A Multi‑Center, Open‑Label, Single‑Arm Trial to Evaluate the Efficacy, Pharmacokinetics, and Safety and Tolerability of IGSC 20% in Subjects with Primary Immunodeficiency.
Manuel SantamariaOlaf NethJo A DouglassGergely KrivanRobin KobbeEwa BernatowskaSofia GrigoriadouClaire BethuneAnita ChandraGerd HorneffMichael BorteAnja SonnenscheinPavlina KralickovaSilvia Sánchez RamónDaman LangguthLuis Ignacio González-GranadoLaia AlsinaMontse QueroltRhonda GriffinCarrie HamesElsa MondouJeffrey PriceAna SanzJiang LinPublished in: Journal of clinical immunology (2022)
IGSC 20% demonstrated efficacy and good safety and tolerability in subjects with PI.